Takeda

Our Neuchatel manufacturing site in Switzerland marked a new milestone, celebrating with a ribbon cutting a nearly $250 million expansion. The new manufacturing line will support increased production capacity for our treatments for rare and genetic diseases, such as bleeding disorders. The largest single investment made at the site is also accelerating our digital transformation in manufacturing, with increased use of data-driven automation that positions us for future opportunities. The project includes a new aseptic filling building encompassing formulation, filling line, freeze-drying, capping and automated visual inspection, as well as the expansion of an existing facility to house a new bioreactor. #PatientCommitment #Innovation #PatientCentric #RareDisease

Planetary health is inextricably linked to human health. Our partnership with VELA Transport is an example of pioneering innovation designed to help us reach our ambitious climate goals. As the first biopharmaceutical company to partner with VELA to transport medicines between Europe and the United States using a wind-powered trimaran sailboat, we will leverage an ultra-low-emission distribution option. Find out more about how operational excellence and environmental sustainability can go hand in hand: https://lnkd.in/e-9hCseB #SustainableLogistics #NetZero #SustainableSupplyChain #SustainablePharma #ClimateAndHealth #GreenInnovation #OurStories

TYK2 mediates the immune and inflammatory signaling pathways fundamental to psoriasis, psoriatic arthritis and other immune-mediated inflammatory diseases (IMIDs). Ongoing research into the underlying mechanisms of these diseases continues to deepen our understanding of TYK2 biology to help meet the needs of people living with IMIDs: https://lnkd.in/ewSTcahZ

Alpha-1 antitrypsin deficiency (AATD)—which can cause damage in the liver and/or lungs—is inherited. It is not caused by lifestyle choices. Despite its serious nature, there is still low awareness of the condition, and it remains largely underdiagnosed. Frank, who lives with the most severe form, has become a passionate advocate for better education around Alpha-1, encouraging a holistic and informed approach to this systemic disease. As we wrap up Alpha-1 Awareness Month, we encourage you to watch and share Frank’s story: https://lnkd.in/e9hYVsPc #Alpha1Awareness Everyone’s experience with AATD is different. This information is for disease awareness only and is not medical advice. Always consult a health care professional for medical advice, diagnosis or management. Frank is a paid consultant for Takeda.

AI and digital tools are reshaping how we work, learn and grow. Digital dexterity means embracing new ways to use data, technology and innovation to drive progress and make an impact. #TeamTakeda #MakeHistoryChangeFutures #FutureOfHealth #InnovationDriven

Heading into end-of-year celebrations, let’s make sure the holidays are inclusive for those living with #CeliacDisease (CeD).   Small acts, such as limiting cross-contamination and offering gluten-free choices, can help friends and family avoid unintentional exposure. Explore more practical tips from the National Celiac Association: https://lnkd.in/eMwTgUiV  This content is for general information only. Please consult your healthcare provider for medical advice. 

We’re hiring for Commercial roles across the globe. From Development to delivery, this is where purpose meets potential—where people who are driven to make a difference can shape the future of healthcare. If you’re ready to grow your career with an organization that leads with values and acts with impact, explore open roles today: https://bit.ly/3XEYLJO #TeamTakeda #MakeHistoryChangeFutures #NowHiring #BioPharmaHiring

For people living with #psoriasis (PsO), the diagnosis and treatment journey can look very different depending on where they live, their access to healthcare and the support they receive along the way. By advancing research through global collaboration, we hope to make care more equitable for the PsO community: https://lnkd.in/eeQP-ct4

We’re grateful for our time at American Society of Nephrology's #KidneyWk, where we connected with the global kidney community and shared key research updates on our efforts to advance how autoimmune diseases like IgA nephropathy are treated. #Nephrology

In some parts of the world, only an estimated 10% of people living with alpha-1 antitrypsin deficiency (AATD) have received a diagnosis. For many, stigma and low awareness complicate early detection, potentially leading to delayed care and an increased risk of serious health complications. But a different future may be possible. A simple blood test can detect Alpha-1, helping individuals and their families make informed decisions about their care. This #Alpha1Awareness Month, we’re sharing Lorrinda’s story–a powerful reminder of the impact that delayed diagnosis can have on people living with genetic conditions like Alpha-1. Watch her full story: https://lnkd.in/eKywyEgD Everyone’s experience with AATD is different. This information is for disease awareness only and is not medical advice. Always consult a health care professional for medical advice, diagnosis or management. Lorrinda is a paid consultant for Takeda.